Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-12
2005-07-12
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S362000
Reexamination Certificate
active
06916818
ABSTRACT:
Described herein are compounds with affinity for the 5-HT6receptor, which have the general formula I:wherein:R represents a group of Formula II or Formula III;one of A, B D or E is a N atom, the remainder being CH groups;R1is selected from the group consisting of SO2Ar, C(O)Ar, CH2Ar and Ar;R2, R3and R4are independently selected from the group consisting of H and alkyl;— represents a single or double bond, with the proviso that there is only one double bond in the ring at a time;n is an integer of from1-3;Z is selected from the group consisting of C, CH and N, provided that when —is a double bond, Z is C and when — is a single bond, Z is selected from CH and N;Ar is an optionally substituted aryl group;with the proviso that when R is a group of Formula II, R1is SO2Ar.Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT6receptor is implicated, such as schizophrenia.
REFERENCES:
patent: 6191141 (2001-02-01), Edwards et al.
patent: 6686374 (2004-02-01), Edwards et al.
patent: 0623618 (1994-11-01), None
patent: 0623618 (1994-11-01), None
patent: 0812826 (1997-12-01), None
patent: 0875513 (1998-11-01), None
patent: WO 00/17198 (2000-03-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Rodgers, D.C., et al.,Psycholopharmacology158:114-119, 2001.
Robichaud, A.J., et al.,Ann. Reports Med. Chem.38:11-20, 2000.
Lindner, M.C., “Medline Abstract 9398584,”Neurobiol. Learn Mem.68:203-220, 1997.
Bartus, R.T.,Exper. Neur.,163:495-529, 2000.
Shannon, K.,Curr. Opin. Neurol.9:298-302, 1996.
“Developments in the Treatment of Parkinson's Disease”,Drug Therap. Bull.35:36-40, 1997.
L. Rowland, M.D. and N. Shneide, “Amyotrophic Lateral Sclerosis,”N. Engl. J. Med.344(22):1688-1700, May 31, 2001.
Al-Chalabi A, Leigh PN, “Recent advances in amyotrophic lateral sclerosis,”Curr. Opin. Neurol.13(4):397-405, Aug. 2000.
Edwards Louise
Slassi Abdelmalik
Tehim Ashok
Xin Tao
McKenzie Thomas C.
NPS Allelix Corp.
Rothwell, Figg Ernst & Manbeck, PC
LandOfFree
Azaindoles having serotonin receptor affinity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azaindoles having serotonin receptor affinity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azaindoles having serotonin receptor affinity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3397780